The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of real-world (RW) pomalidomide (pom) dosing patterns in patients (pts) with multiple myeloma (MM) from the Flatiron database.
 
Binod Dhakal
Honoraria - Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Sanofi
Consulting or Advisory Role - Amgen; Arcellx; Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Natera; Pfizer; Sanofi; Takeda
Speakers' Bureau - Janssen Oncology
Research Funding - Amgen (Inst); Arcellx (Inst); Bristol-Myers Squibb/Celgene (Inst); CARsgen Therapeutics (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Sanofi (Inst)
 
Amandeep Godara
Consulting or Advisory Role - Janssen
Other Relationship - Genzyme
 
Eva Medvedova
No Relationships to Disclose
 
Seema Naik
Honoraria - ADC Therapeutics; Janssen Biotech; Janssen Biotech; Millennium; Sanofi
Consulting or Advisory Role - Millennium; Sanofi
Speakers' Bureau - Onclive
Research Funding - Genentech/Roche (Inst)
 
Ajay K. Nooka
Honoraria - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb/Celgene; Cellectar; Genzyme; GlaxoSmithKline; Janssen Oncology; K36 therapeutics; ONK Therapeutics; Pfizer; Secura Bio; Takeda
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; BeyondSpring Pharmaceuticals; Bristol-Myers Squibb; Cellectar; Genzyme; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Oncopeptides; ONK Therapeutics; Pfizer; Secura Bio; Takeda
Research Funding - Amgen (Inst); Arch Oncology (Inst); Bristol-Myers Squibb/Celgene (Inst); Cellectar (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Trilok V. Parekh
Employment - JJ Innovative Medicine
Stock and Other Ownership Interests - JJ Innovative Medicine; Lilly
 
David Hadley
Employment - Janssen Research & Development
 
Ankit J. Kansagra
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Larry D. Anderson, Jr
Honoraria - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; GlaxoSmithKline; janssen; Karyopharm Therapeutics; Oncopeptides; Prothena
Consulting or Advisory Role - Abbvie; amgen; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; GlaxoSmithKline; janssen; Karyopharm Therapeutics; Oncopeptides; Prothena
Research Funding - amgen; bms; celgene; GlaxoSmithKline; janssen; Karyopharm Therapeutics